Nature Medicine, Published online: 07 August 2025; doi:10.1038/s41591-025-03802-8
In this prespecified exploratory biomarker analysis of the placebo-controlled CheckMate 274 trial, a composite model of adaptive immunity biomarkers and clinical parameters was identified and shown to predict benefit from nivolumab treatment in patients with muscle-invasive urothelial cancer.
